ESSA Pharma logo
EPIX logo

ESSA PharmaNasdaqCM:EPIX Stock Report

Market Cap US$75.0m
Share Price
n/a
1Y-84.1%
7D-3.7%
Portfolio Value
View

EPIX Stock Overview

A clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. More details

EPIX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

ESSA Pharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ESSA Pharma
Historical stock prices
Current Share PriceUS$1.68
52 Week HighUS$11.67
52 Week LowUS$1.40
Beta1.61
1 Month Change-9.68%
3 Month Change-1.75%
1 Year Change-84.06%
3 Year Change-84.00%
5 Year Change-68.12%
Change since IPO-98.10%

Recent News & Updates

Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

Aug 21
Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

Recent updates

Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

Aug 21
Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

Feb 18
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Aug 16
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Jan 25
Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

Dec 15
We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

Feb 02

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

Jan 13

ESSA Pharma EPS beats by $0.02

Dec 15

Shareholder Returns

EPIXUS BiotechsUS Market
7D-3.7%1.3%-0.3%
1Y-84.1%-2.3%22.7%

Return vs Industry: EPIX underperformed the US Biotechs industry which returned -2.8% over the past year.

Return vs Market: EPIX underperformed the US Market which returned 22.2% over the past year.

Price Volatility

Is EPIX's price volatile compared to industry and market?
EPIX volatility
EPIX Average Weekly Movement5.0%
Biotechs Industry Average Movement11.3%
Market Average Movement6.4%
10% most volatile stocks in US Market18.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: EPIX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: EPIX's weekly volatility has decreased from 14% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200935David Parkinsonwww.essapharma.com

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.

ESSA Pharma Inc. Fundamentals Summary

How do ESSA Pharma's earnings and revenue compare to its market cap?
EPIX fundamental statistics
Market capUS$75.02m
Earnings (TTM)-US$28.54m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EPIX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$28.54m
Earnings-US$28.54m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.64
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did EPIX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/04 08:47
End of Day Share Price 2025/02/04 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ESSA Pharma Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurice RaycroftJefferies LLC
Soumit RoyJonesTrading Institutional Services, LLC
Leland GershellOppenheimer & Co. Inc.